The FDA approved ribociclib, a CDK4/6 inhibitor, providing an additional treatment option for patients with early breast cancer at high risk for recurrence.

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...